Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019

Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019

Shots:

  • The P-IIIB/IV study results involve assessing of Xeljanz XR (11 mg, qd) as monothx. followed by MTX withdrawal vs Xeljanz XR + MTX in 530 patients in ratio (1:1) with moderate to severe rheumatoid arthritis
  •  The P-IIIB/IV study results: @24-48 wks., LS mean changes in Disease Activity Score (DAS28-4 [ESR]) (0.33 vs 0.03); AEs (40.5% vs 41.0%); SAEs (3.8% vs 1.9%), will be presented at EULAR 2019
  • Xeljanz XR is JAK inhibitor and has received approval in 130+ countries including the US for moderately to severely active rheumatoid arthritis, ulcerative colitis and psoriatic arthritis

Click here to read full press release/ article | Ref: Pfizer | Image: Fortune